The FDA issued the alert on Friday, as per FDA's website. A spokesman for Ranbaxy did not have immediate comment on the FDA action.

Brokerage HSBC in a research note on Monday downgraded Ranbaxy, controlled by Japan's Daiichi Sankyo Co (4568.T), to "underweight" from "overweight" citing the import alert.

The company in May had pleaded guilty to US felony charges related to drug safety and agreed to USD 500 million in fines.


Latest News  from Business News Desk